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EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO 
(ICER) THRESHOLD RANGE IN KOREA: DISCRETE CHOICE 
EXPERIMENTS
Lee J, Ko S
Pﬁzer Korea, Seoul, South Korea
OBJECTIVES: This study was performed to elicit ICER threshold range in Korea and 
to investigate the magnitude of relative inﬂuence of main attributes to reimbursement 
decision. METHODS: This study was based on experts survey using discrete choice 
experiments (DCE). DCE is stated preference method, in which respondents are 
requested to express preferences for sets of hypothetical choice alternatives constructed 
according to experimental design principles. Total 39 respondents (22 from the gov-
ernment or academia and 17 from industry) were responded to this survey among 95 
selected experts who were working in pharmacoeconomics ﬁeld. We identiﬁed 6 
attributes (disease severity, availability of alternative therapy, burden of disease, ICER, 
uncertainty of cost-effectiveness ratio and budget impact) which are considered as 
main decision factors for reimbursement decision. Literatures related to reimburse-
ment decision in Australia, UK, Canada and Korea were comprehensively investigated 
to elicit these attributes. 18 choice sets having two alternatives were selected using 
fractional factorial design (FFD). Each coefﬁcient of 6 attributes and probabilities of 
a recommendation response by ICER range were estimated. RESULTS: Total 1346 
observations were analyzed using probit model. 4 attributes (severity, burden, alterna-
tive, ICER) signiﬁcantly inﬂuenced on respondents’ choice on reimbursement decision 
(p  0.001). If the disease is severe and rare, the probability of recommending the 
alternative as cost-effective is higher. The lower ICER, the higher the probability of 
choosing the alternatives. ICER range threshold from survey results is 70,000,000 
KRW approximately. If industry group were excluded in the analysis, the ﬁgure 
reduced to 40,000,000 KRW. CONCLUSIONS: This study showed that severity, 
burden, alternative, ICER is important factor for reimbursement decision in Korea as 
well expected. The ICER threshold estimated from this study between the estimators 
from previous studies. The study design and/or respondent characteristics could affect 
these ﬁgures.
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IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN 
PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING 
ADMINISTRATIVE DATABASES
Bérard A, Nakhai-Pour HR, Kulaga S
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Administrative databases are increasingly being used in perinatal phar-
macoepidemiology. Although such studies have increased statistical power, they are 
prone to biases due to lack of information on potential confounders. Hence, the 
objective was to quantify the degree of bias introduced by the lack of data on smoking 
status and maternal pre-pregnancy weight in the association between gestational 
exposure to antidepressants and the risk of low birth weight (LBW) infants. 
METHODS: The Quebec Pregnancy Registry was used to sample a cohort of women 
who had delivered a liveborn singleton, and answered a self-administered question-
naire on lifestyles during pregnancy and family history. The association between 
antidepressant use during pregnancy and the risk of LBW was calculated unadjusting 
for smoking status and maternal pre-pregnancy weight using the Registry data. The 
association was further estimated adjusting for smoking and maternal pre-pregnancy 
weight using the questionnaire data. Percent bias in the Registry estimate was calcu-
lated using Schneeweiss’ method. RESULTS: Overall, the unadjusted estimate (Regis-
try data) for the association between antidepressant use during pregnancy and the risk 
of LBW was 1.16 (p  .05). Adjusting for smoking status resulted in an estimate of 
0.99 (p  0.05), and for maternal pre-pregnancy weight, 1.19 (p  0.05). The percent 
bias introduced by the non-adjustment for smoking and maternal pre-pregnancy 
weight using only the Registry data was 13%, and did not change the direction of the 
effect. CONCLUSIONS: Although data on potential confounders are often missing in 
perinatal pharmacoepidemiologic studies using administrative databases, the bias that 
results for the non-adjustment does not necessarily invalidate ﬁndings.
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HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL 
TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE
Schön H1, Theobald K2, Schädlich PK3
1CSG mbH, Berlin, Germany, 2Sanoﬁ-Aventis Germany, Frankfurt, Germany, 3IGES Institut 
GmbH, Berlin, Germany
OBJECTIVES: The increasing scientiﬁcness and complexity of non-interventional 
studies is facing new operational and quality management aspects to gain high level 
quality data and results. Therefore it is crucial to implement quality measurements as 
part of the overall study design. METHODS: A non-interventional, comparative 
multicenter, representative cross sectional cost evaluation study was conducted (LIVE-
COM1). The study retrospectively documented and compared diabetes-speciﬁc 
resource utilisation and patient-reported outcomes (PRO) associated with insulin 
administration in patients with type-2 diabetes mellitus over six months. The study 
was performed in accordance with the recommendations to improve quality and 
transparency of non-interventional studies of the German Association of Research-
Based Pharmaceutical Companies and according to Good Epidemiological Practice. A 
detailed study plan, containing scientiﬁc objectives and statistical methods was devel-
oped before start of study and approved by the responsible Ethic Committee. In 
addition a feasibility assessment of the case record forms and PRO-instruments was 
performed in advance. A total of 4000 randomly selected primary care units were 
invited to participate in LIVE-COM. Throughout the study a close telephone monitor-
ing with the sites was implemented, also to ensure the collection of the PRO data from 
the patient. A detailed in-house review of the case record forms, double data entry, 
query resolutions and source data veriﬁcation at 10% of the sites was implemented. 
RESULTS: In total 1731 patients with signed informed consent were included in the 
study at 138 study centres in Germany. Overall only 1.3% of the documented patient 
data showed missing values and the validity of the data was high. Only in rare cases 
imputation algorithms were applied or data were excluded from analyses. CONCLU-
SION: The implementation of data quality management procedures and close contact 
with the study sites can deliver high quality data comparable to clinical studies. 1Long 
Acting Insulin Glargine Versus Insulin Detemir Cost Evaluation Comparison.
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THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE 
AS A POPULATION LABORATORY
Klungel OH1, Rietveld MC2, de Groot MC3, Stolk RP4, Postma MJ5, Leufkens HG1,  
Egberts TC3, Hövels AM6, van de Langerijt L7, Hoes AW3, Grobbee DE3
1Utrecht University, Utrecht, The Netherlands, 2University Medical Center Utrecht, Utrecht,, 
The Netherlands, 3University Medical Center Utrecht, Utrecht, The Netherlands, 4University 
Medical Center Groningen, Groningen, The Netherlands, 5University of Groningen, 
Groningen, The Netherlands, 6GlaxoSmithKline The Netherlands, Zeist, The Netherlands, 
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OBJECTIVES: To optimize routine health care databases in The Netherlands for 
pharmaco-epidemiologic and economic research in order to improve the beneﬁt-risk 
assessment and the assessment of the value of medicines in daily practice. The gap 
between pre-clinical pharmaceutical research and clinical and outcomes research 
hampers optimal beneﬁt-risk assessment and monitoring of new and existing medi-
cines as well as determining their value in daily practice. Although many excellent 
health care databases are available in The Netherlands for pharmaco-epidemiologic 
and –economic research, in isolation these data remain scattered, rather inaccessible 
and cover relatively inadequate population sample sizes and/or are rather limited in 
detail of the registered information. METHODS: In the ﬁrst phase we have linked 
pharmacy records from the National Foundation of Pharmaceutical Statistics (N  
12,000,000) on a patient base to several routine health care databases such as the 
Almere Health Care database (N  160,000), the Utrecht Health Project (N  20,000), 
and the AGIS claims database (N  1,000,000). To ensure protection of patient 
privacy, pseudonimisation and linkage was performed through a trusted third party 
(TTP). A data catalogue has been developed to allow simple queries over the integrated 
databases which will help in the design of pharmacoepidemiologic studies (incl. sample 
size calculations, assessment of completeness of data). In the second phase, we will 
include several other health care and research databases in The Netherlands (Lifelines, 
Interaction database (IADB), and the Northern GP registration). RESULTS: The pro-
posed research program will deliver a strong, large-scale, high-quality, internationally 
competitive data platform for innovative pharmaceutical research and provide the 
tools to improve beneﬁt-risk assessment of medicines.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Modeling Methods
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MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC 
SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES 
WITH DIFFERENT SEROTYPES
Endel G1, Schiller - Frühwirth I1, Popper N2, Miksch F2, Zauner G2, Breitenecker F3
1Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, 
2DWH—Simulation Services, Vienna, Vienna, Austria, 3Vienna University of Technology, 
Vienna, Vienna, Austria
OBJECTIVES: For modeling vaccination strategies and spreading of infectious dis-
eases by airborne infection or contact transmission detailed individual based simula-
tion is needed. A new technique modeling heterogeneous populations with age speciﬁc 
behavior and population dynamics during simulation is presented. METHODS: A 
multi agent based model is implemented. Requirements: Simulate long periods for long 
term effects; consider changing population structure; implement a social model to 
simulate individual contacts; and simulate various pathogens to differentiate between 
vaccine-covered and non-covered serotypesThe model consists of three parts. Popula-
tion part. Individual attributes for agents: Age, Gender, Infection State, Pregnancy 
(women only) and a unique ID-Number, Age Class and Infection Protocol are stored. 
Aging, Death and Birth of Agents is implemented. Parameters can be identiﬁed with 
real population data of Austria provided by “Statistik Austria”. Social part. Epidemics 
can be spread only through direct contact between two agents. Contacts can happen 
at home, at work, and randomly. Additional rules (f.e. age distribution of people in 
contact depending on the age of the persons) are deﬁned. Epidemics part. The proce-
dure of the epidemics part is depicting the contact based infections, carrying time and 
end of illness, including, time and age speciﬁc carrying time of special bacterial strains. 
Extra features for simulation of two or more pathogens in parallel are developed. 
RESULTS: The concept has been validated using detailed data for serious pneumococ-
cal indicated diseases for Austria. Stability analysis and dependency on starting param-
eters was examined. Results show stable realistic behavior for single serotype and 
competing serotypes. CONCLUSIONS: Using this dynamic modeling concept simula-
tion of non linear effects like herd immunity and serotype replacement is possible for 
